Open AccessCONCEPT OF 505 (b) (2) APPLICATION: BENEFITS AND CHALLENGES
Author(s) -
K Chaitanya Prasad,
M Prabodh,
S Ashish,
R Suthakaran
Publication year - 2018
Publication title -
international journal of drug regulatory affairs
Language(s) - English
Resource type - Journals
eISSN - 2321-7162
pISSN - 2321-6794
DOI - 10.22270/ijdra.v2i2.127
Subject(s) - agency (philosophy) , food and drug administration , section (typography) , business , competition (biology) , antecedent (behavioral psychology) , drug , law and economics , risk analysis (engineering) , medicine , advertising , psychology , pharmacology , economics , social psychology , sociology , ecology , social science , biology
A 505(b) (2) application is a new drug application (NDA) delineated in section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.505(b)(2) application is one that one or a lot of the investigations relied upon by the applicant for approval "were not conducted by or for the applicant and has not obtained a right of reference or use from the person by or for whom the investigations were conducted. Section 505(b) (2) was added to FFDC Act by the Drug price competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The applicant will depend on either revealed literature or agency’s findings of an antecedent approved drug. This approval route was designed to encourage innovation and to eliminate expensive and long duplicative clinical studies.